Skip to content

BELLICUM PHARMACEUTICALS, INC

Delisted

CIK 1358403fmd_1TD13EMF43R7DTGM0X1AA6NHN5Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Sep 30, 2023, 40 periods

Latest annual · FY2022

Millions
Total revenues
2
Gross profit
1
Operating income
(27)
Net income
(25)
Free cash flow
(26)

Latest quarter · Q3 FY2023

Millions
Total revenues
1
Operating income
(1)
Net income
(1)
Free cash flow
(2)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2019 to FY2022
-40.6%
Revenue, 5 yearsFY2017 to FY2022
+52.0%
Net income, 5 yearsFY2017 to FY2022
n/m

BELLICUM PHARMACEUTICALS, INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$1.5 million$6.2 million-75.8%10-K 2023-03-31 · proof
Operating income-$27 million-$24.9 million10-K 2023-03-31 · proof
Net income-$25 million-$9.7 million10-K 2023-03-31 · proof
Cash from operating activities-$25.8 million-$23.1 million10-K 2023-03-31 · proof
Free cash flow-$25.8 million-$23.1 million10-K 2023-03-31 · proof
Total assets$23.8 million$49.1 million-51.5%10-K 2023-03-31 · proof
Total liabilities$3.8 million$6.7 million-43.8%10-K 2023-03-31 · proof
Cash and cash equivalents$21.8 million$46.2 million-52.7%10-K 2023-03-31 · proof
What was BELLICUM PHARMACEUTICALS, INC's revenue in fiscal 2022?
BELLICUM PHARMACEUTICALS, INC reported revenue of $1.5 million for fiscal 2022 (the year ended Dec 31, 2022), against $6.2 million the year before (-75.8%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What was BELLICUM PHARMACEUTICALS, INC's operating income in fiscal 2022?
BELLICUM PHARMACEUTICALS, INC reported operating income of -$27 million for fiscal 2022 (the year ended Dec 31, 2022), against -$24.9 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What was BELLICUM PHARMACEUTICALS, INC's net income in fiscal 2022?
BELLICUM PHARMACEUTICALS, INC reported net income of -$25 million for fiscal 2022 (the year ended Dec 31, 2022), against -$9.7 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What was BELLICUM PHARMACEUTICALS, INC's cash from operating activities in fiscal 2022?
BELLICUM PHARMACEUTICALS, INC reported cash from operating activities of -$25.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$23.1 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What was BELLICUM PHARMACEUTICALS, INC's free cash flow in fiscal 2022?
BELLICUM PHARMACEUTICALS, INC reported free cash flow of -$25.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$23.1 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What are BELLICUM PHARMACEUTICALS, INC's total assets?
As of Dec 31, 2022, BELLICUM PHARMACEUTICALS, INC reported total assets of $23.8 million, against $49.1 million a year earlier (-51.5%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What are BELLICUM PHARMACEUTICALS, INC's total liabilities?
As of Dec 31, 2022, BELLICUM PHARMACEUTICALS, INC reported total liabilities of $3.8 million, against $6.7 million a year earlier (-43.8%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
What are BELLICUM PHARMACEUTICALS, INC's cash and cash equivalents?
As of Dec 31, 2022, BELLICUM PHARMACEUTICALS, INC reported cash and cash equivalents of $21.8 million, against $46.2 million a year earlier (-52.7%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1358403&period_type=annual&limit=5"

Information only, not investment advice.